Follow The Filings

RZLT Rezolute Inc.

Health Care, filed as REZOLUTE INC (COM NEW), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner
  • Max 3.0%
  • $33M

Who owns this now

Largest portfolio weights among holders, up to 3.0% (James Silverman, Opaleye Management). Not free-float ownership.

  1. James Silverman 3.0%

Who owns RZLT

Sorted by value, long equity only, as of 2026 Q2.

History
James Silverman, Opaleye Management 3.0% Hold 6,300,000 $33M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by RZLT's executives, directors and 10% owners in the last 12 months, from their Form 4s

All RZLT insider trades
  • $236K bought by 5 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Daron Evans CFO
    Buy
    $29K 10,000 shares at $2.85 +2.5% to stake
    Traded Mar 30 Filed Mar 31
    ↗
  2. Wladimir Hogenhuis Director
    Buy
    $9,549 5,650 shares at $1.69 +5% to stake
    Traded Dec 16, 2025 Filed Dec 17, 2025
    ↗
  3. Brian Kenneth Roberts Chief Medical Officer
    Buy
    $48K 28,000 shares at $1.70 +10% to stake
    Traded Dec 16, 2025 Filed Dec 17, 2025
    ↗
  4. Daron Evans CFO
    Buy
    $80K 45,000 shares at $1.77
    Traded Dec 15, 2025 Filed Dec 15, 2025
    ↗
  5. Nevan C Elam CEO
    Buy
    $51K 32,000 shares at $1.59 +5.3% to stake
    Traded Dec 15, 2025 Filed Dec 15, 2025
    ↗
  6. Sunil Ratilal Karnawat Chief Commercial Officer
    Buy
    $20K 12,100 shares at $1.62 +20% to stake
    Traded Dec 15, 2025 Filed Dec 15, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 10 stock grants, 7 share withholdings for taxes, and 3 gifts.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
DEF 14A Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025 FY2026
Net income -$51.79M -$68.46M -$74.41M -$77.59M

Balance sheet

Metric FY2023 FY2024 FY2025 FY2026
Total current assets $104.91M $128.65M $171.14M $110.51M
Total non-current assets * $18.81M $4.08M $4.34M $2.34M
Total assets $123.72M $132.74M $175.49M $112.85M
Total current liabilities $5.2M $9.61M $11.91M $11.42M
Total non-current liabilities * $2.35M $2.13M $1.45M $0.744M
Total equity $116.17M $121M $162.13M $100.69M

Cash flow

Metric FY2023 FY2024 FY2025 FY2026
Cash from operations -$44.48M -$57.37M -$69.08M -$64.64M
Cash from investing -$101.46M $48.7M -$14.54M -$21.1M
Cash from financing $11.57M $63.03M $107.33M $2.24M
Net change in cash -$134.37M $54.36M $23.71M -$83.49M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.